CURX

Curanex Pharmaceuticals Inc

$6.09

-1.77%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Source: Yahoo Finance
Q-Score16/ 100
Market Cap$9.6M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta1.32
AI summary

Price & performance

1M+13.5%
3M+28.1%
YTD-29.3%
1Y-61.1%
52-week range—
Beta1.32
Full chart and returns against a benchmark

Q-Score

16/ 100

Quality against peers; 50 is the peer median.

Growth—
Risk24
Performance21
Valuation29
Profitability16
Leverage34
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$4.2M
Net margin—
Historical fundamentals

Red flags in filings

2active red flags
Material weakness in controlsMar 30, 2026
Late filing noticeNov 17, 2025
Filings, findings and the timeline

Valuation

CURXIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B1.996.22PEG—4.02
Dividend yield0.00%
Every valuation metric